Next 10 |
home / stock / medxf / medxf news
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's c...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event : ...
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) to...
2024-02-08 13:16:03 ET Medexus Pharmaceuticals Inc. (MEDXF) Q3 2024 Earnings Conference Call February 8, 2024 8:00 AM ET Company Participants Victoria Rutherford – Investor Relations Ken d’Entremont – Chief Executive Officer Marcel Konrad ...
Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharm...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 20...
Topical terbinafine has been widely used in other markets to treat fungal nail infections If and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million on an annual basis* Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2...
2023-11-11 12:39:13 ET Medexus Pharmaceuticals, Inc. (MEDXF) Q2 2024 Earnings Conference Call November 07, 2023 08:00 AM ET Company Participants Magda Gardner - IR Representative, Adelaide Capital Kenneth d'Entremont - Chief Executive Officer and Director Marcel ...
Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performance Management to host conference call at 8:00 AM Eastern time on Thursday, November 9, 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - Novemb...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, 2023 to discuss Medexus's results for its second fiscal quarter ended September 30, ...
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc Company Name:
MEDXF Stock Symbol:
OTCMKTS Market:
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's c...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event : ...
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) to...